ONCOSEC MEDICAL Inc: Nasdaq/NYSE listing notice — OncoSec receives Nasdaq delisting notice for negative equity of $(984,449)

ONCOSEC MEDICAL Inc

Stockholders' equity was $(984,449) as of Oct 31, 2022, below Nasdaq's $2.5M minimum.
Company has until Feb 10, 2023 to submit a compliance plan; if accepted, up to 180 days to regain compliance.
Failure to regain compliance could lead to delisting, reduced liquidity, and impaired financing.
OncoSec is evaluating options and intends to submit a plan to Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ONCOSEC MEDICAL Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

December 27, 2022, OncoSec Medical Incorporated (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The Company reported stockholders’ equity of $(984,449) in its quarterly report on Form 10-Q for the period ended October 31, 2022, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). The Notice has no immediate impact on the listing of the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-22-036682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.